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OBJECTIVES We sought to assess risk stratification by using dobutamine stress echocardiography (DSE) in
patients with aortic stenosis (AS) and severe left ventricular (LV) dysfunction.
BACKGROUND Few data are available on risk stratification for valve replacement in patients with AS, LV
dysfunction and low transvalvular gradients.
METHODS Low-dose DSE was performed in 45 patients (16 women and 29 men; median [quartile
range] age in years: 75 [69 to 79]; left ventricular ejection fraction: 0.29 [0.23 to 0.32]; aortic
valve area [cm2]: 0.7 [0.5 to 0.8]; mean transaortic gradient [mm Hg]: 26 [21 to 33]). Patients
were classified into two groups: group I (n 5 32, LV contractile reserve on DSE) and group
II (n 5 13, no contractile reserve). Valve replacement was performed in 24 and 6 patients in
groups I and II, respectively.
RESULTS Perioperative mortality was 8% in group I and 50% in group II (p 5 0.014). Survival at five
years after the operation was 88% in group I. Compared with medical therapy, valve surgery
was associated with better long-term survival in group I (hazard ratio for death [HR-D] 0.13,
95% confidence interval [CI] 0.002 to 0.49) and reduced survival in group II (HR-D 19.6,
95% CI 2.7 to 142). The effect of valve surgery on survival remained significant in both groups
after adjustment for age, diabetes, respiratory disease and hypertension. Medical therapy had
the same effect in both groups.
CONCLUSIONS In patients with AS, LV dysfunction and low transvalvular gradients, contractile reserve on
DSE is associated with a low operative risk and good long-term prognosis after valve surgery.
In contrast, operative mortality remains high in the absence of contractile reserve. (J Am Coll
Cardiol 2001;37:2101–7) © 2001 by the American College of Cardiology
Valve replacement is the only effective treatment for patients
with severe aortic stenosis (AS) and congestive heart failure
(1), although perioperative mortality is increased in case of
left ventricular (LV) dysfunction (2) and low transvalvular
pressure gradients (3–5). In previous studies, operative
mortality in the setting of low transvalvular gradients has
been reported to be as high as 33% (4), with no clinical or
hemodynamic variables to stratify operative risk (4,6). Fur-
thermore, some patients may have LV dysfunction due to
primary cardiomyopathy, with only moderate AS, and may
not benefit from valve surgery (3). Dobutamine stress
echocardiography (DSE) has been proposed in patients with
AS and low pressure gradients (7) to calculate the aortic
valve area (AVA) at two different flow states, in order to
identify the patients who are likely to benefit from valve
replacement. However, the study of deFilippi et al. (7) was
limited by a small sample size, due to the infrequent
occurrence of these conditions in a clinical setting. The
present study aimed to assess risk stratification by DSE in a
larger group of patients with severe AS, LV dysfunction and
low transvalvular gradients.
METHODS
Patient selection. Patients were prospectively enrolled be-
tween April 1994 and June 2000 if they had severe native
AS, defined by AVA #1 cm2 (8) with severe LV systolic
dysfunction (left ventricular ejection fraction [LVEF]
#30%) or a mean (transaortic) pressure gradient (MPG)
#40 mm Hg. Exclusion criteria were atrial fibrillation, more
than mild aortic regurgitation and severe comorbidities.
Forty-eight patients met the inclusion criteria, two of whom
were excluded for atrial fibrillation and one for cardiac
amyloidosis. Thus, 45 patients form the basis of this report.
The study protocol was approved by the Review Board of
our institution; informed consent was obtained from all
patients before the investigations.
Doppler echocardiography. A complete Doppler echocar-
diographic study was performed with commercially available
equipment (128 XP-10c or Sequoia C 256, Acuson, Moun-
tainview, California). Left ventricular outflow track
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(LVOT) velocities were recorded in the apical view: the
Doppler sample volume was located just below the aortic
valve and advanced as close as possible before spectral
broadening. Special care was taken to maintain the sample
volume location throughout the stress hemodynamic study.
Stroke volume (SV) was calculated according to standard
formulae (9). Transaortic flow was recorded with continu-
ous wave Doppler using a multiwindow approach (9);
transaortic gradients were calculated using the simplified
Bernoulli equation (10). Aortic valve area was calculated by
the continuity equation (11). Aortic valve resistance was
calculated according to the standard formula (12). For each
Doppler measurement, high-quality tracings were obtained
and three to five cycles were averaged, avoiding post-
extrasystolic beats. Cine loops were stored in the apical four-
chamber and two-chamber views for LVEF calculation.
Dobutamine stress hemodynamic study. After the base-
line study, a dobutamine infusion was begun at 5 mg/kg
body weight per min, titrated upward in steps of 2.5 mg/kg
per min every 5 min up to a maximal dose of 20 mg/kg per
min. The dobutamine infusion was stopped when the
maximal dose or heart rate acceleration $10 beats/min was
reached. Systemic blood pressure and the 12-lead electro-
cardiogram were monitored throughout the test. Bi-apical
cine loops, LVOT and transaortic Doppler tracings were
stored at the end of each step; the dose increment was
delayed until all recordings were considered optimal. The
maximal transaortic velocities were recorded in the apical
view in all but one patient in whom the right parasternal
approach was used.
Clinical decisions and follow-up. The final therapeutic
decision for each individual patient was left to the discretion
of the referring physicians, who had knowledge of the
results of DSE. Clinical data at follow-up were obtained in
all patients at a median interval of 24 months (range 8 to 39)
by direct patient examination or telephone interview by the
referring physician. A complete Doppler echocardiographic
study was obtained 12 months (range 6 to 26) after valve
surgery in 18 of the 21 surviving patients, including mea-
surement of LVEF in 16 patients. Evaluated end points at
follow-up were survival, New York Heart Association
(NYHA) functional class and echocardiographically dem-
onstrated LVEF.
Data analysis. The stress hemodynamic studies were eval-
uated off-line by a single experienced echocardiographer
(V.G.) who had no knowledge of the clinical data, using the
software of the echocardiographic equipment to calculate
gradients, SV, AVA, valve resistance and LVEF by the
bi-plane Simpson’s rule (13). When image quality was
inadequate, LVEF was not assessed. According to a re-
ported mean variability in LVOT Doppler measurements of
5% to 7.5% (14–16), LV contractile reserve on DSE was
defined by an increase in SV of $20%. Patients were
classified into two groups according to the presence (group
I) or absence (group II) of contractile reserve on DSE. The
follow-up studies were evaluated in separate sessions by the
same observer.
Statistical analysis. Continuous data are presented as me-
dian values and corresponding 25th and 75th percentiles.
Dichotomous data are presented as percentages. Statistical
analysis was performed using nonparametric statistical tests.
The chi-square test or Fisher exact test was applied for
dichotomous and categorical data. The Mann-Whitney U
test was used to compare numeric data of the two groups.
The relative risk of postoperative death was determined
using the standard formula. Survival was represented by
Kaplan-Meier curves. A Cox proportional hazards analysis
was performed to assess the independent influence of valve
surgery on survival in each group, with and without adjust-
ments for baseline age, diabetes, hypertension and chronic
obstructive pulmonary disease.
Two-tailed p values ,0.05 were considered statistically
significant. Analyses were done on a personal computer
using Stata software (version 5.0 for Windows, Stata Corp.,
College Station, Texas).
RESULTS
Clinical characteristics. For the whole group, baseline
characteristics included age (years: 75 [69 to 79]), LVEF
0.29 (0.23 to 0.32), cardiac index (l/min per m2: 1.9 [1.6 to
2.2]), AVA (cm2: 0.7 [0.5 to 0.8]), indexed AVA (cm2/m2:
0.4 [0.3 to 0.4]), MPG (mm Hg: 26 [21 to 33]) and valve
resistance (dyneszszcm25: 227 [191 to 304]). Coronary
angiography was performed in 37 patients and showed no
significant coronary artery disease (CAD) in 18 patients;
one-, two- or three-vessel disease was present in three, six
and six patients, respectively; and four patients had previous
patent coronary artery bypass graft surgery (CABG).
The baseline clinical and hemodynamic characteristics by
group are presented in Table 1. Patients were slightly older
in group II than in group I (p 5 0.04), otherwise there were
no group differences in gender ratio, comorbidities, NYHA
functional class, associated CAD, medical treatment or
baseline hemodynamic data. At the time of their first
evaluation, all patients presented with symptoms of conges-
tive heart failure; associated symptoms were angina in two
patients and syncope in two other patients.
Abbreviations and Acronyms
AS 5 aortic stenosis
AVA 5 aortic valve area
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
DSE 5 dobutamine stress echocardiography
LV 5 left ventricle or ventricular
LVEF 5 left ventricular ejection fraction
LVOT 5 left ventricular outflow tract
MPG 5 mean pressure gradient
NYHA 5 New York Heart Association
SV 5 stroke volume
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Dobutamine stress hemodynamic studies. Data from the
DSE studies are listed in Table 2. There were no group
differences in dobutamine peak dose, peak heart rate or peak
blood pressure. All studies were terminated for attainment
of a maximal dose or heart rate acceleration $10 beats/min.
The mean duration of the DSE studies was 29 min (range
22 to 37). The test was well tolerated in all patients, with no
sustained arrhythmia, no sign of ischemia and no fall in
blood pressure. Premature ventricular or atrial contractions
occurred in seven patients.
Changes in Doppler echocardiographic indexes with
dobutamine. As predefined, group I was characterized by
an increase in SV concordant with an increase in LVEF on
DSE (p , 0.001 vs. baseline). In contrast, there was no
significant change in LVEF with dobutamine in group II
(p 5 0.11 vs. baseline).
In group I, MPG and AVA increased significantly (p ,
0.0001 and p , 0.001, respectively, vs. baseline). In eight
patients in group I, AVA remained stable, whereas AVA
increased by 0.1, 0.2, 0.3 and 0.4 cm2 in 14, 5, 3 and 2
patients, respectively. Thus, final AVA was 1 cm2 in three
patients, whereas it remained ,1 cm2 in one patient
(despite an increase in AVA by 0.4 cm2). Only one patient
in the whole group had a final AVA .1 cm2, which
increased from 0.9 to 1.3 cm2. Valve resistance did not
change significantly in group I (p 5 0.07 vs. baseline).
Table 1. Baseline Clinical and Hemodynamic Data by Group
Variable
Group I
(n 5 32)
Group II
(n 5 13) p Value
Age (yrs) 74 (64–78) 79 (73–82) 0.04
Gender (M/F) 19/13 10/3 0.26
NYHA functional class (I/II/III/IV) 0/6/18/8 0/4/7/2 0.61
CAD (1/2/3-vessel) 2/3/3 1/3/3 0.15
Previous AMI 7 (22%) 2 (15%) 0.69
Systemic hypertension 10 (31%) 3 (23%) 0.58
Diabetes mellitus 6 (19%) 1 (8%) 0.35
Renal disease 1 (3%) 3 (23%) 0.12
Respiratory disease 2 (6%) 2 (15%) 0.33
Diuretics 23 (62%) 9 (69%) 0.81
ACE inhibitors 14 (44%) 3 (23%) 0.25
Heart rate (beats/min) 76 (69–87) 82 (72–90) 0.33
SBP (mm Hg) 106 (95–119) 96 (86–117) 0.24
SV (ml) 43 (34–52) 46 (31–49) 0.98
LVEF 0.29 (0.23–0.35) 0.28 (0.20–0.30) 0.44
CI (l/min per m2) 1.9 (1.6–2.1) 2.1 (1.7–2.5) 0.73
AVA (cm2) 0.7 (0.5–0.8) 0.7 (0.6–0.8) 0.84
Indexed AVA (cm2/m2) 0.4 (0.3–0.4) 0.4 (0.3–0.4) 0.51
MPG (mm Hg) 26 (21–34) 30 (22–33) 0.80
Resistance (dyneszszcm25) 223 (183–288) 249 (190–322) 0.53
Data are presented as the median value (25th–75th percentiles) or number (%) of patients.
ACE 5 angiotensin-converting enzyme; AMI 5 acute myocardial infarction; AVA 5 aortic valve area; CAD 5 coronary
artery disease; CI 5 cardiac index; LVEF 5 left ventricular ejection fraction; M/F 5 male/female; MPG 5 mean pressure
gradient; NYHA 5 New York Heart Association; SBP 5 systolic blood pressure; SV 5 stroke volume.
Table 2. Data From the Dobutamine Stress Echocardiographic Studies by Group
Variable
Group I
(n 5 32)
Group II
(n 5 13) p Value
Dobutamine peak dose (mg/kg per min) 8 (7.5–10) 12.5 (7.5–14) 0.07
DHeart rate (beats/min) 10 (5–13) 12 (8–14) 0.11
Peak SBP (mm Hg) 118 (103–132) 102 (89–132) 0.37
Peak SV (ml) 59 (48–70) 49 (35–52) 0.02
DSV (%) 34 (29–53) 8 (7–13) 0.0001
Peak LVEF 0.40 (0.32–0.49) 0.31 (0.20–0.35) 0.007
DLVEF 0.12 (0.07–0.13) 0.03 (0.02–0.05) 0.0001
Peak CI 2.8 (2.6–3.3) 2.7 (2.2–3.2) 0.47
DCI (%) 49 (42–74) 24 (18–37) 0.0001
Peak AVA (cm2) 0.8 (0.6–0.9) 0.8 (0.5–0.8) 0.18
DAVA (%) 17 (8–29) 5 (23–8) 0.006
Peak MPG (mm Hg) 41 (32–51) 30 (24–41) 0.13
DMPG (%) 38 (31–45) 20 (14–30) 0.0002
Peak resistance (dyneszszcm25) 251 (194–307) 244 (187–352) 0.83
DResistance (%) 9 (26–20) 8 (24–24) 0.88
Data are expressed as peak dose values, variation (D) from baseline (international units) or percent variation (D) from baseline.
Abbreviations as in Table 1.
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In group II, MPG also increased, although less than that
in group I. In contrast, there was no significant change in
AVA (p 5 0.15 vs. baseline) or valve resistance (p 5 0.24 vs.
baseline) in this group.
Clinical outcomes. THERAPEUTIC DECISIONS. In group I,
valve replacement was performed in 24 patients, with
concomitant CABG in eight patients; surgical inspection of
the valve showed marked leaflet calcification and severely
reduced leaflet mobility in all patients. The remaining eight
patients in group I were treated medically for the following
reasons: patient refusal for the operation (n 5 3), older age
and comorbidities (n 5 2) and AVA considered outside the
severe range by the referring physician (n 5 3). In group II,
six patients underwent valve replacement (including four
with concomitant CABG), whereas seven patients were
treated medically due to patient refusal (n 5 2), age and
comorbidities (n 5 4) and AVA considered outside the
severe range (n 5 1).
PERIOPERATIVE MORTALITY. Perioperative (30-day) mor-
tality was 8% in group I (2 of 24 patients) and 50% in group
II (3 of 6 patients). The five deaths were caused by pump
failure in all patients: three patients could not be weaned
from cardiopulmonary bypass and the two other patients
died two and three days, respectively, after valve surgery.
The relative risk of perioperative death was 6.0 in group II
(95% confidence interval 1.3 to 28; p 5 0.014). Coronary
artery bypass graft surgery was not associated with a higher
perioperative mortality in group II (p 5 0.4).
LONG-TERM SURVIVAL. In group I, one other patient died
of a mesenteric infarction three months after valve surgery.
Among the eight patients in group I who were treated
medically, seven died of sudden death (n 5 2), end-stage
heart failure (n 5 4) or respiratory disease (n 5 1). Among
the five patients in group I with an increase in AVA of
$0.3 cm2 on DSE who were treated medically, four died at
a median interval of 12 months (two from sudden death and
two from congestive heart failure). In these four patients,
valve replacement was not performed due to patient refusal
in two and AVA considered outside the severe range in two;
coronary angiography had shown no significant disease in
one patient and two-vessel disease in one and was not
performed in the two remaining patients. The only patient
from group I to be alive at five years of follow-up, with
medical therapy, had a final AVA of 1.3 cm2 on DSE,
normal coronary arteries and cardiomyopathy due to alcohol
abuse, which improved with medical treatment.
In group II, one patient died three months after valve
replacement from heart failure. Of the seven patients who
were treated medically, five died at five months (3 to 6) of
follow-up due to sudden death (n 5 1), heart failure (n 5
2) or respiratory disease (n 5 2).
PREDICTORS OF SURVIVAL. Figure 1 shows the Kaplan-
Meier survival estimates by group and treatment strategy
(medical therapy or valve surgery).
Survival at five years was 88% (21 of 24 patients) in group
I patients who underwent valve surgery. There was no
significant difference in survival of medically treated patients
between group I and II (p 5 0.64). The Cox proportional
hazard analysis indicated that survival duration was im-
proved by valve surgery in group I. In contrast, group II
patients had a better survival with medical therapy (Table 3).
Survival duration with medical therapy was comparable in
both groups. After adjustment for age, diabetes, systemic
hypertension and chronic obstructive pulmonary disease,
survival remained improved by valve surgery in group I, but
not in group II, whereas medical treatment had the same
effect in both groups (Table 4).
POSTOPERATIVE FUNCTIONAL IMPROVEMENT AND LVEF.
Among the 21 patients in group I who survived after valve
replacement, marked functional improvement was noted
(Fig. 2): 17 patients were initially in NYHA functional class
III/IV as compared with only one patient in class III at
follow-up (p 5 0.001 vs. baseline). In addition, LVEF
improved in these patients, from 0.29 (0.23 to 0.35) to 0.44
(0.36 to 0.46) (p , 0.0001 vs. baseline) (Fig. 3). In the two
patients from group II who survived after valve surgery,
NYHA functional class improved moderately in one case
(from IV to III), whereas the other patient remained in class
III.
Figure 1. Kaplan-Meier survival curves by group and treatment. Med 5
medical therapy.
Table 3. Cox Proportional Hazard Analysis of the Effect of
Surgical Treatment on Survival Duration in the Two Groups
Hazard
Ratio for
Death
p
Value
95%
Confidence
Interval
Group 1,
medical therapy
1.0 Reference
Group 2,
medical therapy
1.19 0.77 0.37–3.7
Group 1,
valve surgery
0.13 0.003 0.002–0.49
Group 2,
valve surgery
19.6 0.003 2.7–142
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DISCUSSION
The rare subset of patients with AS, severe LV dysfunction
and low transvalvular pressure gradients represents a com-
mon medical challenge given their dismal spontaneous
prognosis and their high operative risk. Furthermore, some
of them may have primary cardiomyopathy and nonsevere
AS and may not benefit from valve replacement (3,4).
Therefore, new diagnostic methods are needed to accurately
assess the severity of AS and to select the patients who are
likely to benefit from valve surgery. The present study
confirms the feasibility and safety of low-dose DSE in these
patients and demonstrates that in case of contractile reserve,
operative mortality is low and long-term outcome is im-
proved by valve surgery. In contrast, in our series, the
patients without contractile reserve had a high perioperative
mortality and valve surgery did not improve their long-term
survival.
Risk stratification by dobutamine echocardiography. In
previous studies, perioperative mortality after valve replace-
ment in patients with AS and LV dysfunction has been
reported to be between 11% and 33% (4,6,14). Blitz et al.
(14) reported a perioperative mortality rate of 11% in a
series of 52 patients with AS and moderate LV dysfunction
(mean LVEF 0.48 6 0.20). The preoperative data from our
patients indicate more severely impaired LV function,
comparable to the series of Brogan et al. (4) and Connolly
et al. (6), who reported perioperative mortality rates of 33%
and 21%, respectively. In the present study, a contractile
reserve on DSE was associated with a perioperative mortal-
ity rate of 8%, dramatically decreased compared with the
aforementioned studies (4,6). This difference in mortality,
compared with the rates reported previously, could partly be
due to improved surgical and anesthesia technique over
time. Nevertheless, the striking difference in operative
mortality between the patients with and those without
contractile reserve in our study supports the idea that DSE
is useful to stratify operative risk. Of note, previous studies
failed to identify any preoperative variables to stratify
operative risk (4,6); the only predictor of surgical mortality
was a postoperative variable (small-size aortic prosthesis)
reported by Connolly et al. (6). Moreover, LV contractile
reserve was associated with 88% survival five years after valve
replacement, thus predictive of long-term outcome, whereas
in previous studies, long-term survival was only influenced
by the absence of CAD (14).
Changes in Doppler indexes and valve area with dobut-
amine. We found an increase in AVA and MPG in group
I of 17% and 58%, respectively, whereas valve resistance
increased by only 9%; these results are concordant with
previous reports (15–17) and support the fact that valve
resistance is less flow-dependent than AVA. deFilippi et al.
(7) defined relative AS by an increase in AVA $0.3 cm2 on
DSE and reported a favorable mid-term outcome with
medical therapy in five such patients. Of note, all five of
these patients had a final AVA .1 cm2 and were considered
as having primary cardiomyopathy associated with moderate
AS (7). Five patients from our series also had an increase in
AVA $0.3 cm2 on DSE, but only one patient had a final
AVA clearly outside the severe range (.1 cm2); the four
remaining patients had a poor outcome with medical
therapy. We cannot determine whether LV dysfunction in
these four patients was due to primary cardiomyopathy or
significant AS, given their final AVA borderline to the
Figure 2. Preoperative and postoperative New York Heart Association
(NYHA) functional classes of the 21 patients in group I who survived after
valve replacement.
Figure 3. Left ventricular ejection fractions (LVEF) before (preop) and
after (postop) valve replacement in group I patients. Open circles represent
individual patient data (n 5 16); solid horizontal lines indicate median
values; and hatched boxes indicate quartiles.
Table 4. Cox Proportional Hazard Analysis of the Effect of
Surgical Treatment on Survival Duration in the Two Groups
After Adjustment for Baseline Age, Diabetes, Hypertension and
Chronic Obstructive Pulmonary Disease
Hazard
Ratio for
Death
p
Value
95%
Confidence
Interval
Group 1,
medical therapy
1.0 Reference
Group 2,
medical therapy
1.07 0.916 0.32–3.5
Group 1,
valve surgery
0.13 0.015 0.02–0.67
Group 2,
valve surgery
31.7 0.002 3.4–295
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severe range (8). Our data, added to those of deFilippi et al.
(7), suggest that relative AS should be defined by an increase
in AVA $0.3 cm2 and a final AVA .1 cm2 on DSE; this
setting was very infrequent in our series (1 in 45 patients).
Justification for a low-dose protocol. Previous studies in
patients with AS (7,15,16,18,19) have used higher doses of
dobutamine and attained up to 85% of the maximal pre-
dicted heart rate (18). This raises the issue of inducing
myocardial ischemia in patients with frequently associated
CAD (5,7,18). Pop et al. (19) reported numerous side
effects of DSE by aiming at 80% of the maximal predicted
heart rate. Furthermore, Lin et al. (18) reported a decrease
in LVEF at a mean dose of 27 6 11 mg/kg per min in
patients with associated CAD.
The goal of inotropic stimulation is to optimize LVEF by
recruitment of contractile reserve, without inducing isch-
emia; in our experience, this can be achieved without a
significant acceleration in heart rate (20). Therefore, we
defined an increase in heart rate $10 beats/min as an end
point for test termination. Nevertheless, we observed sig-
nificant increases in SV, cardiac output and LVEF that
clearly separated the patients with from those without
contractile reserve, concordant with LVEF changes in each
group. Given the simplicity and good reproducibility of
Doppler LVOT measurements (21–23), we found that a
20% increase in SV was a reliable cut point to assess LV
contractile reserve in patients with AS and LV dysfunction.
Postoperative improvement in LVEF. Median LVEF
improved in group I patients after valve replacement, from
0.29 to 0.44. This improvement compares favorably with
the mean increase of 10 6 14 ejection fraction units after
valve replacement reported by Connolly et al. (6). Although
modest, this increase in LVEF is important for patients
with severely impaired LV function and is probably related
to their improved survival and functional status, like in other
patients with cardiomyopathy (24).
Study limitations. The relatively small number of patients
included in this study reflects the infrequent occurrence of
AS with low transvalvular gradients in clinical practice.
These patients represented 5% of all patients referred to our
laboratory for evaluation of AS during the enrollment
period; a similar prevalence has been reported by others
(6,14). To the best of our knowledge, no larger study of
DSE in such patients has been published to date.
Furthermore, the subgroup of patients without contrac-
tile reserve (group II) who underwent valve surgery repre-
sents only six patients. Nevertheless, operative mortality in
these patients was significantly higher than that in group I,
and valve surgery did not improve their long-term survival.
Thus, our data support the idea that DSE may be valuable
for risk stratification, although no definitive conclusions can
be drawn from this small subgroup, especially for therapeu-
tic implications.
Very few patients from our series underwent complete
cardiac catheterization, so we cannot compare invasive and
noninvasive data on cardiac output, gradients or valve area.
Nevertheless, Doppler echocardiographic measurements of
valve gradients and valve area in patients with AS have been
largely validated (11,21,25–27) and are widely recognized as
reliable (8).
Patients from this series were not randomized for treat-
ment, because it seemed unethical given the dismal spon-
taneous prognosis in this group. From an ethical standpoint,
it seemed that therapeutic decisions for each individual
patient had to be made by the referring physicians according
to current practice guidelines.
Conclusions. The present study confirms the feasibility
and safety of low-dose DSE in patients with severe AS, LV
dysfunction and low transvalvular pressure gradients. Our
results demonstrate that the presence of contractile reserve
on DSE is associated with a low operative risk and a good
long-term prognosis, whereas operative mortality remains
high in the absence of contractile reserve. Larger prospective
studies are needed to confirm the prognostic value of DSE
in these patients.
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